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Background: Age at onset (AO) in Machado–Joseph disease (MJD) is closely associated
with the length of the CAG repeat at the mutant ATXN3 allele, but there are other inter-
vening factors. Experimental evidence indicates that the normal ATXN3 allele and the
C-terminal heat shock protein 70 (Hsp70)-interacting protein (CHIP ) may be genetic modi-
fiers of AO in MJD. Methods:To investigate this hypothesis, we determined the length of
normal and expanded CAG repeats at the ATXN3 gene in 210 unrelated patients with MJD.
In addition, we genotyped five single nucleotide polymorphisms (SNPs) within the CHIP
gene. We first compared the frequencies of the different genotypes in two subgroups of
patients who were highly discordant for AO after correction for the length of the expanded
CAG allele.The possible modifier effect of each gene was then evaluated in a stepwise mul-
tiple linear regression model. Results: AO was associated with the length of the expanded
CAG allele (r2=0.596, p<0.001). Frequencies of the normal CAG repeats at the ATXN3
gene and of CHIP polymorphisms did not differ significantly between groups with highly
discordant ages at onset. However, addition of the normal allele improved the model fit
for prediction of AO (r 2=0.604, p=0.014). Indeed, we found that the normal CAG allele
at ATXN3 had a positive independent effect on AO. Conclusion: The normal CAG repeat
at the ATXN3 gene has a small but significant influence on AO of MJD.
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INTRODUCTION
Machado–Joseph disease [MJD, also named spinocerebellar ataxia
(SCA) type 3 (SCA3)], is the most common autosomal dominant
SCA worldwide (Schols et al., 2004). It is caused by an unstable
trinucleotide (CAG) repeat expansion in exon 10 of the ATXN3
gene, which leads to an elongated polyglutamine (PolyQ) tract in
the encoded protein, ataxin-3 (ATXN3; Kawaguchi et al., 1994).
MJD belongs to a group of neurodegenerative disorders (polyQ
diseases) caused by these unstable mutations, such as SCAs 1, 2, 6,
7, and Huntington disease (HD; Everett and Wood, 2004). These
disorders usually begin in early adulthood and slowly progress
over time, and there is significant phenotypic variability (Everett
and Wood, 2004; Schols et al., 2004).
The length of the expanded allele in polyQ disorders is closely
associated with age at onset (AO) of symptoms. In MJD, previous
data indicate that the ATXN3 expansion explains 50–80% of AO
variance (Maciel et al., 1995; Dürr et al., 1996; van de Warrenburg
et al., 2005). Additional environmental and/or genetic factors must
exist that account for the remaining variability. In other polyQ
disorders, some modifier loci and genes have already been identi-
fied (Rubinsztein et al., 1997; Hayes et al., 2000; Pulst et al., 2005;
Metzger et al., 2008). This motivated us to investigate two possible
genetic modifiers of AO in a large sample of unrelated Brazilian
patients with MJD, C-terminal heat shock protein 70 (Hsp70)-
interacting protein (CHIP), and the normal ATXN3 allele.
C-terminal heat shock protein 70 (Hsp70)-interacting pro-
tein is a ubiquitin ligase that was recently shown to suppress
polyQ aggregation in polyQ disorders (Miller et al., 2005; Al-
Ramahi et al., 2006). In cellular and animal MJD models, CHIP
under expression aggravates disease phenotype (Miller et al., 2005;
Williams et al., 2009). Regarding the potential influence of normal
ATXN3, there are conflicting results about its role as an indepen-
dent modifier of AO in MJD (Dürr et al., 1996; van de Warrenburg
et al., 2002). Recent evidence, however, suggests that it interacts
with its mutant counterpart, and this might be relevant in the
pathogenic cascade of neurodegeneration (Jia et al., 2008).
MATERIALS AND METHODS
SUBJECT SELECTION
Two-hundred and ten patients from unrelated families and with
molecular confirmation of MJD were included in the present
study. They were recruited from three neurogenetic centers in
www.frontiersin.org November 2012 | Volume 3 | Article 164 | 1
França et al. Modifier genes in Machado–Joseph disease
southern Brazil: University of Campinas (UNICAMP), University
of Sao Paulo at Ribeirao Preto (USP-RP), and Federal University
of Rio Grande do Sul (UFRGS). This study was approved by our
institution Ethics Committee and written informed consent was
obtained from all participants.
Age at onset was defined as the age at which the first symptoms
of ataxia began. This was estimated according to the reports of
patients and close relatives. Individuals with autosomal dominant
SCA but no molecular confirmation of MJD and those without
available data about AO were excluded from the study.
MOLECULAR STUDIES
Normal and expanded ATXN3 alleles
Genomic DNA (gDNA) was extracted from lymphocytes in
peripheral blood following standard techniques (Sambrook et al.,
1989). We performed polymerase chain reaction (PCR) to deter-
mine the length of the normal and expanded alleles at exon 10 of
ATXN3. The final volume for each assay was 10µl: 50 ng of gDNA;
125µM of each dNTP (dATP, dCTP, dGTP, dTTP); 2.5 pmol of
each primer; Tris-HCl 20 mM; MgCl2 1.75 mM; KCl 50 mM; and
1.5 Units of Taq DNA polymerase. PCR products were resolved
using capillary electrophoresis on MegaBACE™1000 96-capillary
sequencers (GE Healthcare, Buckinghamshire, UK) or ABI3130xl
(Applied Biosystems, Foster City, CA, USA) and length of (CAG)
repeats determined by comparison with standard makers.
CHIP polymorphisms
We selected five single nucleotide polymorphisms (SNPs) in the
CHIP gene, rs12599315, rs11558085, rs11861355, rs6597, and
rs3204090, to genotype in our cohort of patients with MJD.
These polymorphisms were chosen through SNP tagging by
HAPLOVIEW software (Barrett et al., 2005), based on the four
populations evaluated in the HapMap Project (The International
HapMap Consortium, 2005). We used HAPLOVIEW to estimate
minor allele frequency (MAF) and Hardy–Weinberg Equilibrium
(HWE) for these SNPs. We used Real-Time PCR (Applied Biosys-
tems, Foster City, CA, USA) to genotype these SNPs, and each
reaction was performed in a final volume of 7:1µl of DNA; 3.5µl
of TaqMan; 0.175µl of SNP genotyping assay; and 2.325µl of
milliQ water.
STATISTICAL ANALYSIS
We used the G∗Power v.3.1 (Faul et al., 2007) software to evaluate
the post hoc statistical power of the sample to detect associa-
tion with the following parameters: two-tail; effect size= 0.15;
significance level α= 0.01 (corrected for multiple comparisons,
since we analyzed five SNPs); total sample size= 210; number of
predictors= 3.
We then examined the association between AO and the length of
the expanded (CAG) using a linear regression model. This allowed
us to determine the residual AO corrected for expanded (CAG)
for each patient. We selected two groups of patients from the
curve of residual AO, those with extremely early and late onset.
These were defined as patients who had residual AO at least one
standard deviation earlier and later than the mean AO, respec-
tively. We compared the distribution of genotypes and alleles for
the normal ATXN3 allele and for CHIP polymorphisms in the
two groups using the Mann–Whitney U test. Subsequently, we
examined whether the addition of the genotypes for each can-
didate gene as independent variables improved the AO vs. the
expanded (CAG) model in a stepwise regression analysis. Statisti-
cal analysis was performed on SYSTAT 10.2. p Values< 0.05 were
considered significant.
RESULTS
The mean age of onset in the cohort was 35.7 (range 7–64,
SD= 11.3) years. The mean length of expanded and normal
(CAG) repeats was 72 (ranging from 63 to 87, SD= 3.6) and 21
(range 13–37, SD= 5.3), respectively. There was a significant neg-
ative correlation of AO and the (CAG) repeat expansion (Pearson
r2= 0.573, p< 0.001 – Table 1). Logarithmic transformation of
AO led to a slightly better fit [log(r2)= 0.596, p< 0.001], and thus
log-transformed AO was used in all further comparative analyses
(Figure 1).
The SNP average genotype call rate was 100% and the aver-
age genotyping success rate of sample subjects was 100%. Three
CHIP SNPs presented MAF< 0.05, and one was not under HWE
(p< 0.001); therefore these four SNPs were excluded from further
analysis (Table 2).
Table 1 | Predicted ages at onset for each expanded (CAG) length at
the mutant allele in MJD.
Expanded CAG AO 95% CI
60 88 79–98
61 81 73–90
62 76 69–83
63 70 64–76
64 65 60–70
65 60 56–65
66 56 52–59
67 52 49–55
68 48 46–50
69 44 42–46
70 41 40–43
71 38 37–39
72 35 34–36
73 33 32–34
74 30 29–31
75 28 27–29
76 26 25–27
77 24 23–25
78 22 21–24
79 21 19–22
80 19 18–21
81 18 16–19
82 17 15–18
83 15 14–17
84 14 13–16
85 13 12–15
86 12 11–14
87 11 10–13
88 10 9–12
89 10 8–11
90 9 8–10
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Statistical power analysis revealed that the power of our sample
to detect a genetic association was 99.86%. According to residual
AO corrected for expanded (CAG) repeats, there were 34 and 33
patients in the extremely early and late onset groups, respectively.
The mean AO differed significantly between groups (26.4± 8.4
vs. 48.7± 6.3, Mann–Whitney p< 0.001), but there was no sig-
nificant difference in the length of the (CAG) repeat expansion
FIGURE 1 | Scatterplot of age at onset vs. length of expanded (CAG)
repeat atATXN3.
Table 2 | SNPs from CHIP gene evaluated in this cohort.
SNP Position Ch16 (bases) MAF HWE p-value
rs12599315 729831 0.281 <0.001*
rs11558085 730620 <0.05* <0.001*
rs11861355 731517 <0.05* <0.001*
rs6597 731725 0.136 0.345
rs3204090 732465 <0.05* <0.001*
*These SNPs were removed from further analyses due to MAF and/or HWE
status.
(72± 3.7 vs. 71± 3.0, Mann–Whitney p= 0.350). The distribu-
tion of normal ATXN3 (CAG) repeat alleles was also similar in
the two groups (Mann–Whitney p= 0.217, Figure 2A). Allele
and genotype frequencies for rs6597 did not differ between the
two groups (Mann–Whitney p= 0.392 and 0.435, respectively;
Figure 2B).
The inclusion of the normal ATXN3 allele as an independent
variable in the log-transformed AO vs. expanded (CAG) model
resulted in a small but significant improvement in the association
(r2= 0.601, p= 0.034; Table 3). In this combined model, patients
with identical lengths of the (CAG) expansion at the mutant allele
but different lengths at the normal allele would have predicted AO
separated by up to 7 years (Table 4). In contrast, the addition of
rs6597 genotypes as independent variables in the previous model
did not yield a better fit – Table 3.
DISCUSSION
Our results confirm the close association of AO and length of
ATXN3 (CAG) expansion in MJD, which is particularly evident
among patients with large expansions. However, much of the AO
variance cannot be explained by the (CAG) repeat expansion in the
ATXN3 gene, and thus other intervening factors, either environ-
mental or genetic, must also contribute. In other polyQ disorders
such as HD and SCA2, some genetic modifiers have already been
identified, with individual contributions that account for 1–13%
of unexplained AO variability (Rubinsztein et al., 1997; Hayes et al.,
2000; Pulst et al., 2005; Metzger et al., 2008). Although DeStefano
et al. (1996) reported that a familial factor independent of (CAG)
repeat expansion influences AO in MJD, no such genetic modifier
for MJD has been identified to date.
In the present study, there was no significant difference in allele
and genotype frequencies for normal ATXN3 between patients
with extremely late and early onset. This was possibly due to limi-
tations in sample size in either group. However, regression analyses
confirmed that the normal allele indeed has a small (around 1%)
but significant modulating effect on AO. This can be fully appreci-
ated by examining the data presented in Table 4, in which one can
see that patients matched for (CAG) length at the mutant allele
would have a clearly different predicted AO depending on the
FIGURE 2 | Distribution of normalATXN3 (CAG) repeat alleles in the extremely early (black column) and late (dashed column) onset groups (A).
Distribution of genotypes for the SNP rs6597 within the CHIP gene in the extremely early (black column) and late (dashed column) onset groups (B).
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normal alleles they had inherited. Interestingly, this modulating
effect of the normal ATXN3 allele is more relevant for patients with
small expansions at the mutant allele (Table 4). Dürr et al. (1996)
using a different approach, reported similar results in a cohort of
French patients. There is also some evidence that the normal allele
modifies AO in other polyQ disorders, such as SCA1 and SCA6
(van de Warrenburg et al., 2005). The normal HTT allele was also
Table 3 | Multiple linear regression analyses of possible candidate
genetic modifiers of log-transformed age at onset in
Machado–Joseph disease.
Model r2 ∆r2 p-Value
MJD (CAG) exp 0.596 − <0.001
MJD (CAG) exp+normal (CAG) 0.601 0.05 0.034
MJD (CAG) exp+CHIP rs6597 genotype 0.594 0.0 0.452
recently shown to interact with the expanded allele to determine
AO in patients with HD (Aziz et al., 2009). In contrast, authors of
a survey in the Netherlands did not replicate these findings (van
de Warrenburg et al., 2002). That study, however, may have been
underpowered to detect such small modifier effects.
The association of AO and the normal ATXN3 (CAG) repeat
allele suggests that this allele might play a modulatory role in
disease pathogenesis. Although speculative, this possibility is sup-
ported by some experimental and pathologic data. Normal ATXN3
is found in the intraneuronal inclusions characteristic of MJD
(Rüb et al., 2008). Furthermore, cell models in polyQ disorders
have shown that normal proteins interact with the mutant coun-
terparts in a polyQ length-dependent manner and that the rate
of co-aggregate formation (normal+mutant) is proportional to
the polyQ stretch in either the normal or expanded allele (Slepko
et al., 2006). In this scenario, normal ATXN3 with longer polyQ
chains could associate more efficiently with mutant ATXN3. Such
an effect would sequestrate higher amounts of the mutant protein
Table 4 | Predicted ages at onset for each normal (CAG10–40) and expanded (CAG60–90) repeat length in MJD (MLE – maximum likelihood
estimation method).
Expanded CAG Normal CAG
10 15 20 25 30 35 40
60 85 (75–97) 86 (77–97) 88 (78–98) 89 (79–100) 90 (80–102) 92 (80–105) 93 (80–109)
61 79 (70–89) 80 (72–89) 81 (73–90) 82 (74–92) 84 (75–94) 85 (74–97) 86 (74–100)
62 73 (65–82) 74 (67–82) 75 (68–83) 76 (69–84) 77 (70–86) 79 (69–89) 80 (69–92)
63 68 (60–76) 69 (62–76) 70 (64–76) 71 (65–77) 72 (65–79) 73 (65–82) 74 (64–85)
64 63 (56–70) 64 (58–70) 65 (60–70) 66 (60–71) 67 (61–73) 68 (60–76) 69 (60–78)
65 58 (53–64) 59 (54–64) 60 (56–64) 61 (56–65) 62 (57–67) 63 (56–70) 64 (56–72)
66 54 (49–59) 55 (51–59) 55 (52–59) 56 (53–60) 57 (53–62) 58 (52–64) 59 (52–67)
67 50 (46–55) 51 (47–54) 51 (48–54) 52 (49–55) 53 (49–57) 54 (49–59) 55 (48–62)
68 46 (42–50) 47 (44–50) 48 (45–50) 48 (46–51) 49 (46–53) 50 (45–55) 51 (45–57)
69 43 (39–46) 43 (41–46) 44 (42–46) 45 (43–47) 45 (43–48) 46 (42–50) 47 (42–53)
70 40 (37–43) 40 (38–43) 41 (39–43) 41 (40–43) 42 (40–45) 43 (39–47) 43 (39–49)
71 37 (34–40) 37 (35–39) 38 (37–39) 38 (37–40) 39 (37–41) 40 (36–43) 40 (36–45)
72 34 (32–37) 35 (33–36) 35 (34–36) 36 (34–37) 36 (34–38) 37 (34–40) 37 (33–42)
73 32 (29–34) 32 (30–34) 33 (31–34) 33 (32–34) 34 (32–35) 34 (31–37) 35 (31–39)
74 29 (27–32) 30 (28–31) 30 (29–31) 31 (29–32) 31 (29–33) 32 (29–34) 32 (29–36)
75 27 (25–29) 28 (26–29) 28 (27–29) 28 (27–30) 29 (27–31) 29 (27–32) 30 (27–33)
76 25 (23–27) 25 (24–27) 26 (25–27) 26 (25–27) 27 (25–28) 27 (25–30) 27 (25–31)
77 23 (21–25) 24 (22–25) 24 (23–25) 24 (23–26) 25 (23–26) 25 (23–27) 25 (23–29)
78 22 (20–24) 22 (20–23) 22 (21–24) 23 (21–24) 23 (21–25) 23 (21–26) 24 (21–27)
79 20 (18–22) 20 (19–22) 21 (19–22) 21 (20–22) 21 (20–23) 22 (20–24) 22 (19–25)
80 19 (17–20) 19 (17–20) 19 (18–20) 19 (18–21) 20 (18–21) 20 (18–22) 20 (18–23)
81 17 (15–19) 17 (16–19) 18 (16–19) 18 (17–19) 18 (17–20) 18 (17–21) 19 (17–21)
82 16 (14–18) 16 (15–18) 16 (15–18) 17 (15–18) 17 (15–19) 17 (15–19) 17 (15–20)
83 15 (13–17) 15 (13–17) 15 (14–17) 15 (14–17) 16 (14–17) 16 (14–18) 16 (14–19)
84 14 (12–15) 14 (12–15) 14 (13–16) 14 (13–16) 14 (13–16) 15 (13–17) 15 (13–17)
85 13 (11–14) 13 (11–14) 13 (12–15) 13 (12–15) 13 (12–15) 14 (12–16) 14 (12–16)
86 12 (10–13) 12 (10–14) 12 (11–14) 12 (11–14) 12 (11–14) 13 (11–15) 13 (11–15)
87 11 (9–13) 11 (10–13) 11 (10–13) 11 (10–13) 12 (10–13) 12 (10–14) 12 (10–14)
88 10 (9–12) 10 (9–12) 10 (9–12) 11 (9–12) 11 (9–12) 11 (9–13) 11 (9–13)
89 9 (8–11) 9 (8–11) 10 (8–11) 10 (8–11) 10 (9–11) 10 (9–12) 10 (9–12)
90 9 (7–10) 9 (7–10) 9 (8–10) 9 (8–11) 9 (8–11) 9 (8–11) 9 (8–11)
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into the inclusion bodies and avoid its aberrant interactions
with other proteins, thus slowing the neurodegenerative cascade.
Indeed, this pathogenetic model would account for our finding
that the association of (CAG) expansion at the normal allele and
AO is positive.
C-terminal heat shock protein 70 (Hsp70)-interacting protein
is a small protein that acts as a ubiquitin ligase and a co-chaperone
in neurons (Miller et al., 2005; Al-Ramahi et al., 2006). It thus
links two important mechanisms involved in protein quality con-
trol, the ubiquitin proteasome system and the molecular chap-
erones; these mechanisms have been increasingly implicated in
the pathogenesis of polyQ diseases (Orr and Zoghbi, 2007). Evi-
dence from cellular and animal models of MJD indicates that
reduction or elimination of CHIP aggravates disease course and
neuropathological abnormalities (Miller et al., 2005; Williams
et al., 2009). In the face of these results, CHIP was the second
candidate gene to be evaluated. We were left with a single CHIP
SNP, which did not influence AO in our MJD cohort. Despite
this, we believe that rs 6597 provides meaningful information
with which to establish or refute the association because CHIP
is a small gene encompassed by a unique haplotype block in the
populations studied by the HapMap project. This result appar-
ently contrasts with experimental data. A possible explanation is
that CHIP plays an important role in the steps of MJD patho-
genesis occurring after disease onset. An alternative explanation
is that this cohort may just not have sufficient and function-
ally significant variation in CHIP to be detectable by genetic
analysis.
We used two different statistical approaches to test whether
the normal ATXN3 allele and AO are independently associated.
Although the analysis of extremely early and late onset groups
failed to demonstrate significance, the stepwise regression analy-
ses showed an association. This result indeed indicates that the
normal allele modifies AO, and this effect is independent of the
expanded allele effect. In contrast, we were unable to show an asso-
ciation of CHIP polymorphisms with AO. Further research will be
useful to determine whether these findings also hold in individuals
with different ethnic backgrounds and to identify other modifier
genes.
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